Company: TELO
Filing Date: 2025-01-28
Form Type: 8-K
Source: 0001493152-25-003909
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-01-28
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Announces Breakthrough Results with Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential
as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

Oxidative
stress drives aging and is a key factor in diseases like Alzheimer’s, Age-related Macular Degeneration (AMD), cardiovascular diseases,
cancer, and diabetes. It also plays a critical role in the progression of viral infections, such as avian influenza (bird flu), by exacerbating
inflammation and cellular damage. Directly addressing oxidative stress and its consequences is essential to treating the underlying causes
of these conditions and mitigating the severity of viral outbreaks.

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal
science, today announced groundbreaking results from its recent preclinical studies conducted in human cell lines. These studies demonstrated
the ability of Telomir-1 to fully reverse copper-induced elevation of Reactive Oxygen Species (ROS) and provide robust cellular protection
against copper toxicity.

Key
findings from the study include:

  Reversal                                                                                                                               
  Cellular                                                                                                                               
  Regulatory                                                                                                                             

These
findings underscore Telomir-1’s potential to address diseases driven by oxidative stress and copper dysregulation, offering a novel
therapeutic approach to mitigating the cellular damage underlying these conditions.

Cautionary
Note Regarding Forward Looking Statements

This
Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as
“may,” “will,” “expect,” “intend,” “plans,” “anticipate,” “believe,”
“estimate,” “continue” and similar words. Such statements are only predictions and actual events or results may
differ materially from those anticipated in these forward-looking statements. You should not place undue reliance on any forward-looking
statements. In this report, such forward-looking statements relate to the anticipated benefits to the Company of the preclinical study
results disclosed herein, the future of the Company’s development and testing of Telomir-1, and other forward-looking matters related
to the Company’s plans as described herein. Readers are cautioned that actual